Frontiers in Immunology (Dec 2023)

The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy

  • Xinlin Liu,
  • Xinlin Liu,
  • Junwen Deng,
  • Junwen Deng,
  • Renshuai Zhang,
  • Renshuai Zhang,
  • Jiyao Xing,
  • Jiyao Xing,
  • Yudong Wu,
  • Yudong Wu,
  • Wujun Chen,
  • Wujun Chen,
  • Bing Liang,
  • Bing Liang,
  • Dongming Xing,
  • Dongming Xing,
  • Dongming Xing,
  • Jiazhen Xu,
  • Jiazhen Xu,
  • Miao Zhang,
  • Miao Zhang

DOI
https://doi.org/10.3389/fimmu.2023.1335252
Journal volume & issue
Vol. 14

Abstract

Read online

Despite the emergence of molecular targeted therapy and immune checkpoint inhibitors as standard first-line treatments for non-small cell lung cancer (NSCLC), their efficacy in some patients is limited by intrinsic and acquired resistance. Antibody-drug conjugates (ADCs), a revolutionary class of antitumor drugs, have displayed promising clinical outcomes in cancer treatment. In 2022, trastuzumab deruxtecan (Enhertu) was approved for treating HER2-mutated NSCLC, thereby underscoring the clinical value of ADCs in NSCLC treatment strategies. An increasing number of ADCs, focusing on NSCLC, are undergoing clinical trials, potentially positioning them as future treatment options. In this review, we encapsulate recent advancements in the clinical research of novel ADCs for treating NSCLC. Subsequently, we discuss the mechanisms of action, clinical efficacy, and associated limitations of these ADCs.

Keywords